Observational studyDrugs in R&D2020

Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers.

Jacinthe Leclerc et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.